Analysis
Precision Neuroscience closed an oversubscribed $250 million Series D, co-led by Pershing Square Inc., the Ackman Oxman Institute, and an undisclosed life sciences investment fund, according to the company's announcement. Additional participants include the Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures and JSL Health Capital. The round values the company at just over $1 billion.
What Precision Has Actually Built
Founded in 2021, Precision Neuroscience develops a brain-computer interface it calls the Layer 7 cortical interface, a thin, film-like electrode array designed to sit on the surface of the brain rather than penetrate it -- a less invasive approach than the implanted electrode threads used by its best-known rival, Neuralink. Precision has completed more than 100 patient procedures across 18 medical institutions and holds FDA clearance for the Layer 7 device, putting real clinical volume behind a technology category that has mostly generated headlines rather than patient data to date.
“What sets this round apart from a typical med-tech Series D is Pershing Square's involvement.”
The company operates its own wholly-owned MEMS (micro-electromechanical systems) manufacturing facility in Texas, giving it direct control over producing its electrode arrays rather than depending on a third-party contract manufacturer -- a meaningful operational advantage in a hardware category where manufacturing yield and precision are as important as the underlying science. Precision has also formed a commercial partnership with Medtronic, the established medical-device giant, giving it access to a regulatory and sales infrastructure that would otherwise take a standalone startup years to build from scratch.
The Competitive Field And What Makes This Round Different
Precision's most direct competitors are Neuralink, Elon Musk's implant company, and Synchron, which takes a blood-vessel-based approach that avoids open brain surgery entirely; Blackrock Neurotech is a longer-established academic-research-oriented player in the same broad category. Against that field, Precision's surface-based, non-penetrating electrode design and its FDA clearance milestone position it as a nearer-term commercial candidate than approaches still earlier in clinical testing, though the company has not disclosed the specific therapeutic indications closest to a full commercial launch.
What sets this round apart from a typical med-tech Series D is Pershing Square's involvement. Bill Ackman is far better known for public-markets activist investing than early-stage life-sciences venture, and his fund co-leading this round -- alongside the newly formed Ackman Oxman Institute -- brings a different investor profile and a much larger public spotlight to a company that would otherwise be competing for attention against dozens of other well-funded neurotechnology startups. That attention cuts both ways: it raises Precision's visibility with potential commercial and clinical partners, but it also means any setback -- a trial complication, a regulatory delay -- will draw more public scrutiny than a comparable stumble at a less prominently backed competitor.
What To Watch
The total raised to date, $430 million since 2021, funds continued clinical trials and manufacturing scale-up, but the near-term signal worth tracking is whether Precision discloses a specific commercial launch timeline for Layer 7 now that it has FDA clearance and a Medtronic partnership in place -- the gap between regulatory clearance and actual commercial revenue is where several device-hardware startups in adjacent categories have stumbled before.